Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology

Further Publications

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology

J Natl Compr Canc Netw

Loren AW, Mielcarek M, Bolaños-Meade J, Brammer J, Cowden M, Di Stasi A, El-Jawahri A, Elmariah H, Gundabolu K, Gutman J, Ho V, Hoeg RT, Horwitz M, Jamy O, Kassim A, Dabaja MK, Lee L, Logan A, Luszcak C, Magenau JM, Martin TG, Mittal V, Moreira J, Muffly L, Nakamura R, Nawas M, Nieto Y, Ninos C, Oliai C, Papanicolaou G, Pidala J, Randolph B, Schroeder MA, Tessier J, Topal J, Tzachanis D, Varshavsky-Yanovsky AN, Jones F, Stehman K

doi: 10.6004/jnccn.2025.0047

Genitourinary Cancer

Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

J Natl Compr Canc Netw

Balis F, Green DM, Armstrong A, Aye J, Benedetti D, Brown B, Brown E, Cook S, Desai A, Dhillon J, Fair D, Geynisman DM, Hiniker S, Horst K, Jasty-Rao R, Just M, Kieran K, Lin C, MacEwan I, Martinez-Agosto J, Mullen E, Murphy ES, Pinto N, Ranalli M, Rhee D, Rokitka D, Walz A, Wickiser J, Yoon J, Zapala M, Montgomery S, Sliker B

doi: 10.6004/jnccn.2025.0037

SPECIAL REPORT

Genitourinary Cancer

EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer

Further Publications

Use of food restrictions to prevent infections in paediatric patients with cancer and haematopoietic cell transplantation recipients: a systematic review and clinical practice guideline

EClinicalMedicine

Phillips R, Fisher BT, Ladas EJ, Patel P, Robinson PD, Dupuis LL, Ammann RA, Beauchemin MP, Carlesse F, Castagnola E, Davis BL, Efremov K, Elgarten CW, Groll AH, Haeusler GM, Koenig C, Morris A, Santolaya ME, Spinelli D, Tissing WJE, Wolf J, Sung L, Lehrnbecher T

doi: 10.1016/j.eclinm.2025.103093

Breast Cancer

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025

J Natl Compr Canc Netw

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R

doi: 10.6004/jnccn.2025.0053

Genitourinary Cancer

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)

Ann Oncol

Lin HM, Scheinberg T, Portman N, Kim RMN, Mellor R, Hunyh K, Faulkner AN, Mellett NA, Davis ID, Martin A, Sullivan D, Joshua A, McJannett M, Subhash V, Yip S, Azad AA, Marschner IC, North SA, McDermott RS, Chi KN, Stockler MR, Sweeney CJ, Meikle PJ, Horvath LG

doi: 10.1016/j.annonc.2025.05.529

Genitourinary Cancer

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Prostate Cancer Prostatic Dis

Siech C, von Kriegstein H, Wenzel M, Cano Garcia C, Le QC, Tennstedt P, Preisser F, Maurer T, Kriegmair M, Chun FKH, Graefen M, Tilki D, Mandel P

doi: 10.1038/s41391-025-01018-y

Lung, Respiratory and Thoracic Cancer

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†

Ann Oncol

Zer A, Ahn MJ, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, Gautschi O, Hendriks LE, Jänne PA, Kerr KM, Mascaux C, Mitsudomi T, Peters S, Rolfo C, Sacher A, Senan S, Ugalde P, Leighl NB, ESMO Guidelines Committee

doi: 10.1016/j.annonc.2025.08.003

Gynecologic Cancer

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025

J Natl Compr Canc Netw

Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, Brooks R, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R, Glaser S, Howitt BE, Landrum L, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Nieto K, Nwachukwu C, Podoll M, Rodabaugh K, Salani R, Schorge J, Schuetze S, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Sambandam V

doi: 10.6004/jnccn.2025.0038

Related content

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology

Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer

Use of food restrictions to prevent infections in paediatric patients with cancer and haematopoietic cell transplantation recipients: a systematic review and clinical practice guideline

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025